

To: **Lilac Insights**  
 qwwwww eeeee eeeee eefedfsfvesg efef  
 -  
 Contact:  
**Report Of: MRS. DEMO**  
 Pt. Contact:

Sample ID 6200000012  
 Patient ID 6200000012  
 Received on 2024-07-31 12:47:13  
 Registered on 31/07/2024 12:47:13  
 Reported on 31/07/2024 12:47:13  
 Referred by 31/07/2024 12:47:13  
 Sonography by

**EVICOSCREEN - EVIDENCE BASED COMPREHENSIVE PRENATAL SCREENING REPORT**

Patient Name: MRS. DEMO Patient DOB: 01/08/1999

Ethnicity: Asian City: \_\_\_\_\_ Hospital ID: \_\_\_\_\_

Sample Type: Serum Collection Date: 31/07/2024  
 Method: ( )

EVICOScreen™ is an evidence based prenatal screening program curated by Lilac Insights in accordance with the international guidelines for prenatal screening to determine the probability of most common chromosomal aneuploidies in a pregnancy. It utilizes:

- Hormonal values from the pregnancy measured on Fetal Medicine foundation (UK) accredited analyzers and reagents
- Robust indigenous medians from over 5 lac+ pregnancies for different gestation ages
- Risk calculations from evidence based algorithms validated through large international studies
- External audit of the prenatal screening program by United Kingdom National External Quality Assessment Service (UKNEQAS) scheme and Randox International Quality Assessment Scheme (RIQAS)

Test Name	Result.	Units
Free-β-hCG	10	ng/mL
PAPP-A	600	mIU/L

**Note**



*Pradip Kadam*  
 Verified by  
**Mr. Pradip Kadam**  
 Incharge Biochemistry  
 (FMF ID: 147760)

*Suresh Bhanushali*  
 Verified by  
**Dr. Suresh Bhanushali**  
 MD (Path), Consultant Pathologist